Current Studies

Last updated February 18, 2020

vials

Studies currently being conducted by the SIVS Clinical Trials Program.

For more information click on links to go to ClinicalTrials.gov, or call (409) 772 5278.

Recruiting

Current Studies - Recruiting

NCT04199689: Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Recruiting Soon!
Sponsor: Merck Sharp & Dohme Corp.
Principal Investigator: Richard Rupp, MD

For more information click here

NCT04144348: Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12-36 Months of Age With Serologic Evidence of Prior Exposure

Recruiting Soon!
Sponsor: ModernaTX, Inc.
Principal Investigator: Richard Rupp, MD

For more information click here

NCT03537508: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Sponsor: Sanofi Pasteur
Principal Investigator: Richard Rupp, MD

For more information click here

NCT03381196: A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

Sponsor: Janssen Research & Development, LLC
Principal Investigator: Richard Rupp, MD

For more information click here

Active, Not Recruiting

Current Studies - Active, Not Recruiting

NCT03893448: Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (PNEU-PED)

Sponsor: Merck Sharp & Dohme Corp.
Principal Investigator (Galveston): Richard Rupp, MD
Principal Investigator (Bay Colony): Marcela Navarro, MD

For more information click here

NCT03738241: A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered IM With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Richard Rupp, MD

For more information click here

NCT03692871: A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

Sponsor: Merck Sharp & Dohme Corp.
Principal Investigator: Marcela Navarro, MD

For more information click here

NCT03682120: A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59(R) Adjuvant

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Richard Rupp, MD

For more information click here

NCT03620162: A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

Sponsor: Merck Sharp & Dohme Corp.
Principal Investigator: Richard Rupp, MD

For more information click here

NCT03524118: A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants

Sponsor: Merck Sharp & Dohme Corp.
Principal Investigator: Richard Rupp, MD
For more information click here

NCT03512288: Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants (B747-1003)

Sponsor: Pfizer Inc.
Principal Investigator: Richard Rupp, MD

For more information click here

NCT03486834: Safety, Tolerability, and Efficacy of the Human Cytomegalovirus Vaccine (V160) in Healthy Women 16 to 35 Years of Age (V160-002)

Sponsor: Merck Sharp & Dohme Corp
Principal Investigator: Richard Rupp, MD

For more information click here

NCT03480763: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)

Sponsor: Merck Sharp & Dohme Corp.
Principal Investigator: Richard Rupp, MD

For more information click here

NCT03090191: A phase III, placebo-controlled, randomized, observer-blinded, study to evaluate efficacy, and tolerability of a Clostridium difficile vaccine in adults 50 years of age and older (CLOVER)

Sponsor: Pfizer Inc.
Principal Investigator: Richard Rupp, MD

For more information click here